Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | MMP12 | P39900 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 3/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.31 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.31 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561595 | 0.96 | EPHX1 (0.39) | EPHX1MMP1MMP9MMP12MMP2 | |
| SCHEMBL1799225 | 0.95 | EPHX1 (0.42) | EPHX1MMP1MMP9MMP12CCNE1 | |
| SCHEMBL20469204 | 0.92 | CCNE1 (0.38) | CCNE1CDK2GSK3BMGLLSERPINE1 | |
| SCHEMBL9887162 | 0.89 | NPC1 (0.37) | EPHX1MMP1MMP9MMP12MMP2 | |
| SCHEMBL1300090 | 0.87 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12MMP2 | |
| SCHEMBL27365535 | 0.87 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12MMP2 | |
| SCHEMBL31736019 | 0.87 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12MMP2 | |
| SCHEMBL27385617 | 0.87 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12MMP2 | |
| SCHEMBL1300093 | 0.87 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12MMP2 | |
| SCHEMBL18227162 | 0.87 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2693882-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2693882-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2720544-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Marck Sharp & Dohme Corp. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Marck Sharp & Dohme Corp. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Marck Sharp & Dohme Corp. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2900242-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-9006228-B2 | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006228-B2 | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006228-B2 | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | SCHERING CORPORATION | 2011-09-01 | — | — | US | disclosed |
| WO-2011030139-A1 | 4- (PYRIMIDIN-2-YL) -PIPERAZINE AND 4- (PYRIMIDIN-2-YL) -PIPERIDINE DERIVATIVES AS GPR119 MODULATORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | WO | disclosed |
| US-20110065706-A1 | Therapeutic Agents 812 | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
| US-20110003765-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADENOSINE THERAPEUTICS, LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003765-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADENOSINE THERAPEUTICS, LLC | 2011-01-06 | — | — | US | disclosed |
| US-20100093770-A1 | THERAPEUTIC AGENT FOR GLAUCOMA CONTAINING ADENOSINE DERIVATIVE AS ACTIVE INGREDIENT | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-04-15 | — | — | US | disclosed |
| US-20100093770-A1 | THERAPEUTIC AGENT FOR GLAUCOMA CONTAINING ADENOSINE DERIVATIVE AS ACTIVE INGREDIENT | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-04-15 | — | — | US | disclosed |
| WO-2009082720-A2 | SUBSTITUTED 4-{3-[6-AMINO-9-(3,4-DIHYDROXY-TETRAHYDRO-FURAN-2-YL)-9H-PURIN-2-YL]-PROP-2-YNYL}-PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | PGX HEALTH, LLC (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090162292-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162292-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GCGR, GPR139 | EPHX1 1847/4885MMP1 4772/4885MMP9 4348/4885 |
| US-20100093770-A1 | THERAPEUTIC AGENT FOR GLAUCOMA CONTAINING ADENOSINE DERIVATIVE AS ACTIVE INGREDIENT | ADORA2A, PDE2A, PRKG1 | EPHX1 1894/4885MMP1 761/4885MMP9 833/4885 |
| US-20110003765-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | EPHX1 1014/4885MMP1 4506/4885MMP9 4355/4885 |
| US-20090162292-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | EPHX1 1014/4885MMP1 4506/4885MMP9 4355/4885 |
| US-20110065706-A1 | Therapeutic Agents 812 | GPR119, GPR84, GPR132 | EPHX1 1505/4885MMP1 3498/4885MMP9 2188/4885 |
| US-20110212938-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND THEIR USE AS MODULATORS OF THE ACTIVITY OF GPR119 | GPR119, GPR88, GPR180 | EPHX1 2144/4885MMP1 4825/4885MMP9 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.